Jeff Fairman - Jun 28, 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
VP, Research
Signature
/s/ Winston Macaraeg, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Jun 28, 2021
Transactions value $
-$107,267
Form type
4
Date filed
6/30/2021, 05:41 PM
Previous filing
Jun 9, 2021
Next filing
Jul 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $8.5K +4.75K +92.34% $1.79* 9.89K Jun 28, 2021 Direct
transaction PCVX Common Stock Sale -$112K -4.61K -46.63% $24.36 5.28K Jun 28, 2021 Direct F1, F2
transaction PCVX Common Stock Sale -$3.37K -136 -2.58% $24.80 5.14K Jun 28, 2021 Direct F1, F3
holding PCVX Common Stock 341K Jun 28, 2021 By Fairman Family Trust
holding PCVX Common Stock 50K Jun 28, 2021 By AF 2020 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -4.75K -5.49% $0.00 81.8K Jun 28, 2021 Common Stock 4.75K $1.79 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $23.77 to $24.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $24.79 to $24.81. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The shares subject to the option are fully vested and exercisable.